In a phase 2 trial published Oct. 26, 2026, in Cell Metabolism, UBT251, a weekly shot that acts on three gut hormones, lowered HbA1c by up to 2.16% at 24 weeks in adults with type 2 diabetes, vs. 1.77% with…
In a phase 3 trial published Oct. 30, 2026, in The Lancet Diabetes & Endocrinology, Japanese adults with obesity disease who took orforglipron, a once-daily GLP-1 pill, lost 5.9% to 8.7% of their body weight at 72 weeks, vs. 0.6%…
A US records study of 70 257 adults with schizophrenia and type 2 diabetes, published in November 2026 in The Lancet Psychiatry, linked starting a GLP-1 drug to fewer psychiatric hospitalizations than not starting one (hazard ratio 0.76).
In a phase 2 trial published Oct. 28, 2026, in Diabetes Care, adults with type 1 diabetes and overweight or obesity who took acmopatide lost 3.3% to 6.7% of their body weight in 16 weeks, vs. a 0.3% gain on…